DECLINE IN HEALTHCARE RESOURCE CONSUMPTION FOR PATIENTS WITH RHEUMATOID ARTHRITIS STARTING CERTOLIZUMAB PEGOL THERAPY IN FRANCE (THE ECLAIR STUDY)
Author(s)
Saraux A1, Flipo R2, Fagnani F3, Cukierman G4, Joubert J4, Schuller J5, Massol J6, Combe B7
1CHU La Cavale Blanche, Brest, France, 2Hôpital Roger Salengro, Lille, France, 3Cemka-Eval, Bourg-la-Reine, France, 4UCB Pharma, Colombes, France, 5UCB Pharma, Brussels, Belgium, 6CHU de Besançon, Besançon, France, 7CHU Lapeyronie, Montpellier, France
OBJECTIVES: To estimate the healthcare resource consumption of rheumatoid arthritis (RA) patients treated with certolizumab pegol (CZP) during routine clinical practice in France. METHODS: ECLAIR was a prospective, non-interventional, multicenter study conducted in France over three years (2014–2017), in patients with moderate-to-severe, active RA starting first-line treatment with CZP followed during routine clinical practice. This study recruited 170 rheumatologists and 6 internal medicine specialists, and was designed to be representative of the French RA population. Of the 792 enrolled patients, 733 formed the full analysis set (FAS). Here, we describe the frequency of physician consultations, nurse and physiotherapist visits, hospitalisation/emergency room visits and medical procedures for the FAS. Data are reported for patients with 12-month, 24-month and 36-month visit data. RESULTS: In the FAS, healthcare provider consultations related to RA decreased with time; these were reported in 44.6% (243/545), 40.3% (184/457) and 37.4% (82/219) of patients with 12-, 24- and 36-month visit data, respectively. These consultations were mainly performed by rheumatologists and general practitioners. Hospitalisations >1 day in length and emergency room visits also declined with time and were reported, respectively, in 13.0% (71/545) and 7.5% (41/545) of patients with 12-month data; 10.1% (46/457) and 2.4% (11/457) of patients with 24-month data, and 11.4% (25/219) and 2.7% (6/219) of patients with 36-month data. Medical procedures (including magnetic resonance imaging, computerised tomography scans, and scintigraphy) also decreased with time, reported in 47.3% (258/545), 46.0% (210/457) and 32.9% (72/219) of patients documented at 12, 24 and 36 months, respectively. CONCLUSIONS: This was the first prospective, real-world study of an anti-TNF conducted in France, and provides insight on healthcare resource consumption in RA patients treated with CZP. As consultations did not influence the likelihood of patient drop-out, results suggest a decline in resource consumption over time, including physician consultations, hospitalisations/emergency room visits, and medical procedures.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PMS77
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Musculoskeletal Disorders